Brother Enterprises Holding: Brother Enterprises Holding's performance forecast for the first half of 2024.

Sensex a share12:00 ET · Announcements

Brother Enterprises Holding (002562.SZ) mainly focuses on research and development of products in the areas of neurology, metabolism, immunology, and respiration for formulation.

On July 2nd, Gelunhui reported that investors asked Brother Enterprises Holding (002562.SZ) on the investor interactive platform whether the company has rare disease drugs or is developing such drugs. The company replied that their formulations mainly focus on product research and development in the fields of nervous system, metabolism, immune system, and respiratory system. Currently there are no rare disease drugs.

Gelonghui FinanceJul 2 05:11 ET

Even After Rising 19% This Past Week, Brother Enterprises HoldingLtd (SZSE:002562) Shareholders Are Still Down 29% Over the Past Five Years

It's nice to see the Brother Enterprises Holding Co.,Ltd. (SZSE:002562) share price up 19% in a week. But over the last half decade, the stock has not performed well. You would have done a lot bet

Simply Wall StJul 1 19:23 ET

Brother Enterprises Holding (002562.SZ): Some of the iodine contrast agent active pharmaceutical ingredients have been marketed and sold in India, Russia, Ukraine and other markets.

Brother enterprises holding (002562.SZ) stated on the investor interaction platform on June 20th that some of the company's raw materials for iodinated contrast agents have been marketed and sold in India, Russia, Ukraine and other markets, and the company is actively promoting the sales of raw materials for iodinated contrast agents in the global market.

Gelonghui FinanceJun 20 05:28 ET

Brother Enterprises Holding's Q1 2024 financial report analysis: net income declined, improved cash flow situation.

Brother Enterprises Holding (Stock Code: 002562) recently released its Q1 2024 financial report. As a focus of market attention, the report details the company's financial condition and business performance during the reporting period. Here is an in-depth interpretation of Brother Enterprises Holding's Q1 report. First, we focus on the company's asset and liability data. The report shows that the total assets at the end of this reporting period were 5.843 billion yuan, slightly down from the end of the previous year, a decrease of 0.75%. This is mainly due to the structural adjustment of the company's liabilities and equity. In terms of liabilities, although the total amount of liabilities at the end of the period was 2.817 billion yuan, a decrease from the beginning of the period, but...

businesstimes cnJun 13 23:52 ET

Brother Enterprises' Unit Gets Nod to Market Iopamidol in Europe

Brother Enterprises Holding's (SHE:002562) unit, Jiangxi Brother Pharmaceutical, obtained the suitability certificate suitability from the European Directorate for the Quality of Medicines & HealthCar

MT NewswiresMay 20 03:57 ET